ProfileGDS5678 / 1426247_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 92% 92% 91% 90% 91% 92% 93% 92% 90% 91% 91% 91% 91% 90% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 17.5223992
GSM967853U87-EV human glioblastoma xenograft - Control 27.7101492
GSM967854U87-EV human glioblastoma xenograft - Control 37.4142391
GSM967855U87-EV human glioblastoma xenograft - Control 47.3028890
GSM967856U87-EV human glioblastoma xenograft - Control 57.5729791
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 17.4335192
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 27.5438893
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 37.6227792
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 47.2175690
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 17.3772191
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 27.4210291
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 37.3933891
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 47.3363491
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 57.1927490